TriangleNCT02097810 · CITED IN SOURCE DOCUMENTS
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE1
- Status at capture
- COMPLETED
- Registry last update
- 2021-06-09
Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3), ROS1 (coded by the gene ROS1), and ALK (coded by the gene ALK). Molecular alterations to one or more of these targets are present in several different tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), prostate cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma. Patients with locally advanced or metastatic cancer with a detectable molecular alteration in targets of interest may be eligible for enrollment. Phase 1 will assess safety and tolerability of entrectinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and efficacy will be assessed in the dose expansion portion of the study.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Key Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alteration. * Measurable disease according to RECIST version 1.1. * Prior cancer therapy is allowed, including crizotinib, ceritinib, and investigational drugs. * Prior radiotherapy is allowed * Patients with controlled asymptomatic central nervous system involvement are allowed. * Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2. * Adult patients age 18 years or older. * Life expectancy of at least 3 months. Key Exclusion Criteria: * Current participation in another therapeutic clinical trial. * Prior treatment with entrectinib. * History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval \> 450 milliseconds). * History of additional risk factors for torsade de pointes (e.g., family history of long QT syndrome). * Known active infections (bacterial, fungal, viral including HIV positivity). * Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption. * Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis. * Peripheral neuropathy ≥ Grade 2.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Oral entrectinib (RXDX-101)
- intervention Names
- Drug: Entrectinib
- label
- Entrectinib (RXDX-101)
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Entrectinib (RXDX-101)
- name
- Entrectinib
- other Names
- TrkA/TrkB/TrkC/ROS1/ALK inhibitor
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 84
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Determine dose-limiting toxicities of entrectinib.
- measure
- Dose-Limiting Toxicity (DLT)
- time Frame
- 28 days following first dose of entrectinib
- description
- Determine MTD of entrectinib
- measure
- Maximum Tolerated Dose (MTD)
- time Frame
- 28 days following first dose of entrectinib
- description
- Determine RP2D of entrectinib.
- measure
- Recommended Phase 2 Dose (RP2D)
- time Frame
- Approx. 6 months
- description
- Per RECIST v1.1 as assessed by Investigator.
- measure
- Overall Response Rate (ORR) in Dose Expansion
- time Frame
- Approx. 2 months
- secondary Outcomes
- measure
- Plasma Concentrations of Entrectinib
- time Frame
- Cycle 1 Days 1, 7, 14, 28
- description
- Per RECIST v1.1 as assessed by Investigator.
- measure
- Disease Control
- time Frame
- Approx. 2 years
- description
- Per RECIST v1.1 as assessed by Investigator.
- measure
- Duration of Response
- time Frame
- Approx. 2 years
- measure
- Overall Survival (OS)
- time Frame
- Approx. 2 years
- measure
- Progression-Free Survival (PFS)
- time Frame
- Approx. 2 years
Full study description
- brief Summary
- Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3), ROS1 (coded by the gene ROS1), and ALK (coded by the gene ALK). Molecular alterations to one or more of these targets are present in several different tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), prostate cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma. Patients with locally advanced or metastatic cancer with a detectable molecular alteration in targets of interest may be eligible for enrollment. Phase 1 will assess safety and tolerability of entrectinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and efficacy will be assessed in the dose expansion portion of the study.
Source references
- references
- citation
- Yu Y, Fan Y, Dong X, Li J, Yu Y, Zhao J, Tao S, Chen Y, Chen M, Liu Y, Xu J, Zhu Q, Hu X, Lu S. Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison. Lung Cancer. 2024 Dec;198:108018. doi: 10.1016/j.lungcan.2024.108018. Epub 2024 Nov 10.
- pmid
- 39549678
- type
- DERIVED
- citation
- Doebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, Krebs MG, Meropol NJ, Wong WB, Crane G. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021 Dec;10(17):1271-1282. doi: 10.2217/cer-2021-0131. Epub 2021 Aug 24.
- pmid
- 34427452
- type
- DERIVED
- citation
- Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.
- pmid
- 33646820
- type
- DERIVED
- citation
- Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
- pmid
- 31838015
- type
- DERIVED
- citation
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
- pmid
- 31838007
- type
- DERIVED
- citation
- Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman DM, Hechtman J, Wei G, Cam NR, Christiansen J, Luo D, Maneval EC, Bauer T, Patel M, Liu SV, Ou SH, Farago A, Shaw A, Shoemaker RF, Lim J, Hornby Z, Multani P, Ladanyi M, Berger M, Katabi N, Ghossein R, Ho AL. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016 May;27(5):920-6. doi: 10.1093/annonc/mdw042. Epub 2016 Feb 15.
- pmid
- 26884591
- type
- DERIVED
- citation
- Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2015 Dec;10(12):1670-4. doi: 10.1097/01.JTO.0000473485.38553.f0.
- pmid
- 26565381
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-094e3d19bec92e6d2f0e
- requested nct id
- NCT02097810
- primary nct id
- NCT02097810
- source kind
- fda_spl_label
- source record id
- b93e1fc0-614a-4e49-a91d-a409fb2db9f0
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 8f6605e714e630f7a653f3f11f35fabd17a6d2bb66b18a820f52d25e97ce4632
- payload
- application numbers
- NDA212725
- NDA218550
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-094e3d19bec92e6d2f0e
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02097810
- occurrences
- context exact
- dules (90% received ROZLYTREK 600 mg orally once daily) and were enrolled in one of three multicenter, single-arm, open-label clinical trials: ALKA, STARTRK-1 (NCT02097810) and STARTRK-2 (NCT02568267). To be included in this pooled subgroup, patients were required to have histologically confirmed, recurrent or metastatic, ROS1 -p
- end
- 396
- exact text
- NCT02097810
- start
- 385
- context exact
- unresectable or metastatic solid tumors with a NTRK gene fusion enrolled in one of three multicenter, single-arm, open-label clinical trials: ALKA, STARTRK-1 (NCT02097810) and STARTRK-2 (NCT02568267). To be included in this pooled subgroup, patients were required to have progressed following systemic therapy for their disease, i
- end
- 3244
- exact text
- NCT02097810
- start
- 3233
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/25/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- b93e1fc0-614a-4e49-a91d-a409fb2db9f0
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- acef6342ee0fa8a6e940b3b6e959425c12053dff2ecb9cd6e890b6a74f0c239b
- spl effective time
- 20251204
- spl set id
- c7c71b0c-2549-4495-86b6-c2807fa54908
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-0e0750fdb665ef9fa33e
- requested nct id
- NCT02097810
- primary nct id
- NCT02097810
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 68c1706258e98d38c9ed48fd0c71432d06d320b05c8885ceb5fa728eadea7590
- payload sha256
- a53e6026f8f2125745cb0ccc143fef1aa72addff486af5b2094fae08f485adb8
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-0e0750fdb665ef9fa33e
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02097810
- occurrences
- context exact
- ofessional&language=English'); return(false);">Level of evidence C3</a>]</p> <div class="pdq-content-list"><ul id="_290"><li><a href="/clinicaltrials/NCT02097810">ALKA-372-001</a>; adult patients.</li><li><a href="/clinicaltrials/NCT02097810">STARTRK-1</a> (NCT02097810); adult patients.</li><li><a href="/clinicaltrials/
- end
- 39415
- exact text
- NCT02097810
- start
- 39404
- context exact
- <div class="pdq-content-list"><ul id="_290"><li><a href="/clinicaltrials/NCT02097810">ALKA-372-001</a>; adult patients.</li><li><a href="/clinicaltrials/NCT02097810">STARTRK-1</a> (NCT02097810); adult patients.</li><li><a href="/clinicaltrials/NCT02568267">STARTRK-2</a> (NCT02568267); adult patients.</li><li><a href="/clin
- end
- 39495
- exact text
- NCT02097810
- start
- 39484
- context exact
- nt-list"><ul id="_290"><li><a href="/clinicaltrials/NCT02097810">ALKA-372-001</a>; adult patients.</li><li><a href="/clinicaltrials/NCT02097810">STARTRK-1</a> (NCT02097810); adult patients.</li><li><a href="/clinicaltrials/NCT02568267">STARTRK-2</a> (NCT02568267); adult patients.</li><li><a href="/clinicaltrials/NCT02650401">STAR
- end
- 39523
- exact text
- NCT02097810
- start
- 39512
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/673b6b58fe51113964.html
- source file sha256
- 68c1706258e98d38c9ed48fd0c71432d06d320b05c8885ceb5fa728eadea7590
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:27.710469+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- dd1d1d1ad91100ad4c1f7e9f55ba1a72466b1757ab229115c118a2a0940b3724
- source title
- Agnostic Cancer Therapies (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: February 12, 2025
- datetime
- 2025-02-12T12:00:00Z
- display
- February 12, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-baf4865fc71ac806ef61
- requested nct id
- NCT02097810
- primary nct id
- NCT02097810
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
- payload sha256
- bd7215cf0d3091ac71918b1e2d7efdcf84ae4baa9b90b06972322c5495d6be50
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-baf4865fc71ac806ef61
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02097810
- occurrences
- context exact
- determined by integrated analysis of three multicenter, single-arm, open-label clinical trials (ALKA-372-001/EudraCT, 2012-000148-88, <a href="/clinicaltrials/NCT02097810">STARTRK-1</a> [NCT02097810], and <a href="/clinicaltrials/NCT02568267">STARTRK-2</a> [NCT02568267]).[<a href="#cit/section_11.74">74</a>] Entrectinib was give
- end
- 526063
- exact text
- NCT02097810
- start
- 526052
- context exact
- alysis of three multicenter, single-arm, open-label clinical trials (ALKA-372-001/EudraCT, 2012-000148-88, <a href="/clinicaltrials/NCT02097810">STARTRK-1</a> [NCT02097810], and <a href="/clinicaltrials/NCT02568267">STARTRK-2</a> [NCT02568267]).[<a href="#cit/section_11.74">74</a>] Entrectinib was given orally at a dose of at lea
- end
- 526091
- exact text
- NCT02097810
- start
- 526080
- context exact
- s determined by integrated analysis of three early-phase, multicenter, single-arm, open-label clinical trials (ALKA-372-001/EudraCT, 2012-000148-88, STARTRK-1 [NCT02097810], and STARTRK-2 [NCT02568267]).[<a href="#cit/section_11.82">82</a>] Treatment consisted of entrectinib administered orally at a dose of at least 600 mg once
- end
- 538913
- exact text
- NCT02097810
- start
- 538902
- context exact
- determined by integrated analysis of three multicenter, single-arm, open-label clinical trials (ALKA-372-001/EudraCT, 2012-000148-88, <a href="/clinicaltrials/NCT02097810">STARTRK-1</a> [NCT02097810], and <a href="/clinicaltrials/NCT02568267">STARTRK-2</a> [NCT02568267]).[<a href="#cit/section_12.42">42</a>] Entrectinib was giv
- end
- 717310
- exact text
- NCT02097810
- start
- 717299
- context exact
- alysis of three multicenter, single-arm, open-label clinical trials (ALKA-372-001/EudraCT, 2012-000148-88, <a href="/clinicaltrials/NCT02097810">STARTRK-1</a> [NCT02097810], and <a href="/clinicaltrials/NCT02568267">STARTRK-2</a> [NCT02568267]).[<a href="#cit/section_12.42">42</a>] Entrectinib was given orally at a dose of at le
- end
- 717338
- exact text
- NCT02097810
- start
- 717327
- context exact
- y integrated analysis of three early-phase, multicenter, single-arm, open-label clinical trials (ALKA-372-001/EudraCT, 2012-000148-88, <a href="/clinicaltrials/NCT02097810">STARTRK-1</a> [NCT02097810], and <a href="/clinicaltrials/NCT02568267">STARTRK-2</a> [NCT02568267]).[<a href="#cit/section_12.50">50</a>] Treatment consisted
- end
- 730055
- exact text
- NCT02097810
- start
- 730044
- context exact
- ee early-phase, multicenter, single-arm, open-label clinical trials (ALKA-372-001/EudraCT, 2012-000148-88, <a href="/clinicaltrials/NCT02097810">STARTRK-1</a> [NCT02097810], and <a href="/clinicaltrials/NCT02568267">STARTRK-2</a> [NCT02568267]).[<a href="#cit/section_12.50">50</a>] Treatment consisted of entrectinib administered
- end
- 730083
- exact text
- NCT02097810
- start
- 730072
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/11a3437f29dc92742e.html
- source file sha256
- 6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:59.782436+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 96af5062fe49c6481bdc1ef6946e69939f30c810b02e368845c837ccf6c0977c
- source title
- Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: May 15, 2025
- datetime
- 2025-05-15T12:00:00Z
- display
- May 15, 2025
Preserved source evidence · Independent clinical review pending · Not medical advice